blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4012030

EP4012030 - COMPOSITION FOR TREATING OR SENSITIZING INTERFERON BETA RESISTANT CANCER DISEASE COMPRISING CFLIP SIRNA [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  02.02.2024
Database last updated on 31.05.2024
FormerRequest for examination was made
Status updated on  23.12.2022
FormerThe application has been published
Status updated on  13.05.2022
Most recent event   Tooltip29.05.2024New entry: Reply to examination report 
Applicant(s)For all designated states
Abion Inc.
(Gaepo-dong) Room 202 Changwon Bldg. 5
Gaepo-ro 34-gil
Gangnam-gu, Seoul 06309 / KR
For all designated states
Seoul National University R & DB Foundation
Sillim-dong
1 Gwanak-ro
Gwanak-gu
Seoul 08826 / KR
[2022/24]
Inventor(s)01 / SHIN, Young Kee
06279 Seoul / KR
02 / KIM, Tae Eun
14061 Anyang-si Gyeonggi-do / KR
03 / HONG, Sung Youl
22760 Incheon / KR
04 / SONG, Kyoung
03736 Seoul / KR
05 / JUNG, Hun Soon
07963 Seoul / KR
06 / KIM, Joo Seok
06760 Seoul / KR
07 / LEE, Sang Yun
08844 Seoul / KR
 [2022/24]
Representative(s)Richardt Patentanwälte PartG mbB
Wilhelmstraße 7
65185 Wiesbaden / DE
[2022/24]
Application number, filing date21196452.331.07.2017
[2022/24]
Priority number, dateKR2016009751629.07.2016         Original published format: KR 20160097516
[2022/24]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4012030
Date:15.06.2022
Language:EN
[2022/24]
Search report(s)(Supplementary) European search report - dispatched on:EP13.05.2022
ClassificationIPC:C12N15/113, C07K14/565, A61K38/21, A61K31/713, A61P35/00
[2022/24]
CPC:
C12N15/113 (EP); A61K48/00 (EP,KR); A61K38/215 (US);
A61K31/713 (US); A61K38/19 (EP,KR); A61K39/00 (EP,KR);
A61K39/395 (EP); A61K39/3955 (KR); A61P35/00 (US);
C07K14/565 (EP); A61K2039/505 (KR); C12N2310/14 (EP);
C12N2320/31 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/04]
Former [2022/24]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:ZUSAMMENSETZUNG ZUR BEHANDLUNG ODER SENSIBILISIERUNG VON INTERFERON-BETA-RESISTENTER KREBSERKRANKUNG MIT CFLIP-SIRNA[2022/24]
English:COMPOSITION FOR TREATING OR SENSITIZING INTERFERON BETA RESISTANT CANCER DISEASE COMPRISING CFLIP SIRNA[2022/24]
French:COMPOSITION POUR LE TRAITEMENT OU LA SENSIBILISATION DE LA MALADIE CANCÉREUSE RÉSISTANT À L'INTERFÉRON BÊTA COMPRENANT DE L'ARNSI DE CFLIP[2022/24]
Examination procedure14.12.2022Amendment by applicant (claims and/or description)
15.12.2022Examination requested  [2023/04]
15.12.2022Date on which the examining division has become responsible
01.02.2024Despatch of a communication from the examining division (Time limit: M04)
29.05.2024Reply to a communication from the examining division
Parent application(s)   TooltipEP17834832.2  / EP3492107
Fees paidRenewal fee
16.12.2021Renewal fee patent year 03
16.12.2021Renewal fee patent year 04
16.12.2021Renewal fee patent year 05
26.07.2022Renewal fee patent year 06
05.07.2023Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]WO03035868  (RIBOPHARMA AG [DE], et al) [X] 1,8 * claims 1,18,47 * [Y] 2,4,9,10;
 [XY]WO2005053725  (UNIV BELFAST [GB], et al) [X] 1,3,5-8 * page 32; example 6; claims 1-4, 15, 17, 28, 30, 34; sequence 1 * [Y] 2,4,9,10;
 [A]WO2006049423  (SAMSUNG FINE CHEMICALS CO LTD [KR], et al) [A] 1-10 * examples 7-2; claims 1,14-16 *;
 [YA]  - A. APELBAUM ET AL, "Type I Interferons Induce Apoptosis by Balancing cFLIP and Caspase-8 Independent of Death Ligands", MOLECULAR AND CELLULAR BIOLOGY, US, (20130215), vol. 33, no. 4, doi:10.1128/MCB.01430-12, ISSN 0270-7306, pages 800 - 814, XP055459739 [Y] 10 * figure 4 * [A] 1-9

DOI:   http://dx.doi.org/10.1128/MCB.01430-12
 [A]  - JEANETTE BLOMBERG ET AL, "Inhibition of cellular FLICE-like inhibitory protein abolishes insensitivity to interferon-Î and death receptor stimulation in resistant variants of the human U937 cell line", APOPTOSIS ; AN INTERNATIONAL JOURNAL ON PROGRAMMED CELL DEATH, KLUWER ACADEMIC PUBLISHERS, BO, (20110512), vol. 16, no. 8, doi:10.1007/S10495-011-0606-0, ISSN 1573-675X, pages 783 - 794, XP019929331 [A] 1-10 * figures 6,7 *

DOI:   http://dx.doi.org/10.1007/s10495-011-0606-0
 [A]  - ETHIRAJ PURUSHOTH ET AL, "Interferon [beta] improves the efficacy of low dose cisplatin by inhibiting NF-[kappa]B/p-Akt signaling on HeLa cells", BIOMEDICINE AND PHARMACOTHERAPY, ELSEVIER, FR, (20160508), vol. 82, doi:10.1016/J.BIOPHA.2016.04.058, ISSN 0753-3322, pages 124 - 132, XP029678091 [A] 1-10 * figure 1 *

DOI:   http://dx.doi.org/10.1016/j.biopha.2016.04.058
 [A]  - ROSARIO YERBES ET AL, "Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL", INVESTIGATIONAL NEW DRUGS., US, (20101125), vol. 30, no. 2, doi:10.1007/s10637-010-9597-x, ISSN 0167-6997, pages 541 - 547, XP055652259 [A] 1-10 * figure 4 *

DOI:   http://dx.doi.org/10.1007/s10637-010-9597-x
 [A]  - LAUREN T. GATES ET AL, "cFLIP L Interrupts IRF3-CBP-DNA Interactions To Inhibit IRF3-Driven Transcription", THE JOURNAL OF IMMUNOLOGY, (20160718), vol. 197, no. 3, doi:10.4049/jimmunol.1502611, ISSN 0022-1767, pages 923 - 933, XP055652161 [A] 1-10 * figure 8 *

DOI:   http://dx.doi.org/10.4049/jimmunol.1502611
 [A]  - TRAVIS DAY ET AL, "RNA Interference in Cancer: Targeting the Anti-Apoptotic Protein c-FLIP for Drug Discovery", MINI REVIEWS IN MEDICINAL CHEMISTRY, NL, (200906), vol. 9, no. 6, doi:10.2174/138955709788452748, ISSN 1389-5575, pages 741 - 748, XP055652371 [A] 1-10 * table 2 *

DOI:   http://dx.doi.org/10.2174/138955709788452748
 [A]  - D B LONGLEY ET AL, "c-FLIP inhibits chemotherapy-induced colorectal cancer cell death", ONCOGENE, London, (20051017), vol. 25, no. 6, doi:10.1038/sj.onc.1209122, ISSN 0950-9232, pages 838 - 848, XP055233638 [A] 1-10 * figures 1,2,5 *

DOI:   http://dx.doi.org/10.1038/sj.onc.1209122
 [A]  - SHIRLEY SARAH ET AL, "Targeting c-FLIP in cancer", CANCER LETTERS, NEW YORK, NY, US, (20101110), vol. 332, no. 2, doi:10.1016/J.CANLET.2010.10.009, ISSN 0304-3835, pages 141 - 150, XP028545983 [A] 1-10 * table 1 *

DOI:   http://dx.doi.org/10.1016/j.canlet.2010.10.009
 [A]  - BELINDA S. PARKER ET AL, "Antitumour actions of interferons: implications for cancer therapy", NATURE REVIEWS. CANCER, GB, (20160225), vol. 16, no. 3, doi:10.1038/nrc.2016.14, ISSN 1474-175X, pages 131 - 144, XP055325896 [A] 1-10 * page 140; figures 1,3 *

DOI:   http://dx.doi.org/10.1038/nrc.2016.14
 [A]  - KHAM R. TRINH ET AL, "Anti-CD20-Interferon-[beta] Fusion Protein Therapy of Murine B-Cell Lymphomas :", JOURNAL OF IMMUNOTHERAPY, US, (201306), vol. 36, no. 5, doi:10.1097/CJI.0b013e3182993eb9, ISSN 1524-9557, pages 305 - 318, XP055497073 [A] 1-10 * figure 1 *

DOI:   http://dx.doi.org/10.1097/CJI.0b013e3182993eb9
 [XP]  - Tae-Eun Kim ET AL, "Sensitization of glycoengineered interferon-[beta]1a-resistant cancer cells by cFLIP inhibition for enhanced anti-cancer therapy", Oncotarget, United States, vol. 8, no. 8, doi:10.18632/oncotarget.14573, (20170110), pages 13957 - 13970, URL: file:///C:/Users/AB03938/AppData/Local/Temp/14573-216579-3-PB.pdf, XP055652163 [XP] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.18632/oncotarget.14573
by applicantUS5677171
 US5770195
 US5772997
 US2006025885
 KR100781666B
 KR20160097516
    - ARDUINI et al., Protein Science, (19990000), vol. 8, pages 1867 - 1877
    - PILLING et al., European Journal of Immunology, (19990000), vol. 29, pages 1041 - 1050
    - YOUNG et al., Neurology, (19980000), vol. 51, pages 682 - 689
    - CIRELLI et al., Clin Immunother, (19950000), vol. 3, pages 27 - 87
    - PARKER B et al., Nat. Rev. Cancer., (20160000), vol. 16, pages 131 - 144
    - PAVLINKOVA et al., Clin. Cancer Res., (19990000), vol. 5, pages 2613 - 2619
    - SIEVERS et al., Blood, (19990000), vol. 93, pages 3678 - 3684
    - ELLIS et al., J. Immunol., (19950000), vol. 155, pages 925 - 937
    - HERCEPTIN; FORNIER et al., Oncology(Huntingt),, (19990000), vol. 13, pages 647 - 58
    - MAIER et al., Cancer Res., (19910000), vol. 51, pages 5361 - 5369
    - PETERSON et al., Cancer Res., (19970000), vol. 57, pages 1103 - 1108
    - OZZELLO et al., Breast Cancer Res. Treat., (19930000), vol. 25, pages 265 - 276
    - VAN YM et al., Cancer Res., (19960000), vol. 56, pages 5179 - 5185
    - DIVGI et al., Nucl. Med. Biol., (19940000), vol. 21, pages 9 - 15
    - ONO et al., Mol. Immuno.,, (19990000), vol. 36, pages 387 - 395
 WO2016KR02129
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.